Ontology highlight
ABSTRACT:
SUBMITTER: Lux MP
PROVIDER: S-EPMC6357172 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Lux Michael P MP Nabieva Naiba N Hartkopf Andreas D AD Huober Jens J Volz Bernhard B Taran Florin-Andrei FA Overkamp Friedrich F Kolberg Hans-Christian HC Hadji Peyman P Tesch Hans H Häberle Lothar L Ettl Johannes J Lüftner Diana D Wallwiener Markus M Müller Volkmar V Beckmann Matthias W MW Belleville Erik E Wimberger Pauline P Hielscher Carsten C Geberth Matthias M Abenhardt Wolfgang W Kurbacher Christian C Wuerstlein Rachel R Thomssen Christoph C Untch Michael M Fasching Peter A PA Janni Wolfgang W Fehm Tanja N TN Wallwiener Diethelm D Schneeweiss Andreas A Brucker Sara Y SY
Cancers 20181221 1
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 th ...[more]